Skip to main content

Table 1 Baseline demographics and disease characteristics

From: The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial

 

Saxagliptin*

Control*

N

21

21

Age (years), mean ± SD

58.3 ± 5.7

56.4 ± 8.5

Female, n (%)

11 (52%)

7 (33%)

Race, n (%)

 African American

15 (71%)

13 (62%)

 White

5 (24%)

6 (29%)

 Other

1 (5%)

2 (10%)

Weight (lbs), mean ± SD

202.7 ± 24.5

202.3 ± 38.7

BMI (kg/m2), mean ± SD

32.3 ± 4.2

31.5 ± 4.8

Duration of diabetes (years), mean ± SD

3.7 ± 2.4

3.5 ± 1.8

HbA1C mean ± SD

7.0 ± 0.8

6.6 ± 0.5

Fasting glucose (mg/dL), mean ± SD

127.4 ± 35.9

114.8 ± 25.0

eGFR (mL/min/1.73), mean ± SD

98.9 ± 14.5

93.7 ± 16.7

  1. * No significant differences were observed